Anaplastic Large Cell Lymphoma (systemic) · line 2 · Crizotinib 250 mg PO BID continuous — r/r ALK+ ALCL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-CRIZOTINIB-ALCL |
| ID | IND-ALCL-2L-CRIZOTINIB-ALKPOS |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-ALCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for r/r ALK+ ALCL only. Off-label use; UA-accessible via existing NSCLC supply route. Bridge to alloSCT consolidation standard.
Used By
Algorithms
ALGO-ALCL-2L- ALGO-ALCL-2L